Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Philippines’ Zuellig To Produce Generic Versions Of Own Branded Drugs

This article was originally published in PharmAsia News

Executive Summary

Zuellig Pharma Philippines plans to begin selling generic drugs as part of its product line that heretofore has been limited to branded products. The head of the Philippines unit of Zuellig Pharma said the firm intends to produce locally made branded generic versions of its branded drug. It plans to provide its formulations to Interphil Laboratories to produce the lower-cost versions. Kasigod Jamias said that with the generics lines, the company expected to duplicate its 5 percent to 10 percent growth recorded last year. (Click here for more

You may also be interested in...



Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?

Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business. 

Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

UsernamePublicRestriction

Register

SC071603

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel